{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736+%2B+tremelimumab", "query": { "intervention": "MEDI4736 + tremelimumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736+%2B+tremelimumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T20:09:31.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03015129", "title": "A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Endometrial Carcinosarcoma", "Endometrial Carcinoma", "Endometrial Cancer Recurrent", "Endometrial Carcinoma, Recurrent" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2017-01", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015129" }, { "nct_id": "NCT02558894", "title": "Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "MEDI4736 monotherapy", "type": "DRUG" }, { "name": "tremelimumab+MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-11-16", "completion_date": "2017-06-15", "has_results": true, "last_update_posted_date": "2018-08-02", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 2, "location_summary": "Tampa, Florida • New York, New York", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02558894" }, { "nct_id": "NCT03164772", "title": "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "BI 1361849", "type": "BIOLOGICAL" }, { "name": "PharmaJet Tropis® device", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2017-12-20", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Tampa, Florida • Detroit, Michigan + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03164772" }, { "nct_id": "NCT03026062", "title": "Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2017-05-18", "completion_date": "2025-09-11", "has_results": true, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03026062" }, { "nct_id": "NCT06710223", "title": "Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "SD-101", "type": "DRUG" }, { "name": "Cryotherapy", "type": "DEVICE" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2025-01-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06710223" }, { "nct_id": "NCT07489976", "title": "IIT2025-03-YANG-LIFT-HCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepato Cellular Carcinoma" ], "interventions": [ { "name": "STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ju Dong Yang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2026-04-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07489976" }, { "nct_id": "NCT02205333", "title": "A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Aggressive B-cell Lymphomas" ], "interventions": [ { "name": "MEDI6469 Monotherapy", "type": "BIOLOGICAL" }, { "name": "MEDI6469 Plus Tremelimumab", "type": "BIOLOGICAL" }, { "name": "MEDI6469 Plus Durvalumab", "type": "BIOLOGICAL" }, { "name": "MEDI6469 plus Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 48, "start_date": "2014-08-13", "completion_date": "2016-04-08", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02205333" }, { "nct_id": "NCT03618134", "title": "Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Human Papillomavirus Positive", "Oropharyngeal Squamous Cell Carcinoma", "p16 Positive Neoplastic Cells Present", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Modified Radical Neck Dissection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Transoral Robotic Surgery", "type": "PROCEDURE" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2018-10-04", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03618134" }, { "nct_id": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 103, "start_date": "2024-04-04", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 47, "location_summary": "Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008093" }, { "nct_id": "NCT03084471", "title": "An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Solid Malignancies" ], "interventions": [ { "name": "MEDI4736 (Durvalumab)", "type": "BIOLOGICAL" }, { "name": "MEDI4736 (Durvalumab) + Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 867, "start_date": "2017-06-05", "completion_date": "2022-12-16", "has_results": true, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-09-29T20:09:31.375Z", "location_count": 10, "location_summary": "Santa Rosa, California • Washington D.C., District of Columbia • Tinley Park, Illinois + 7 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tinley Park", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03084471" } ] }